Condition: Oral Cavity Squamous Cell Carcinoma · Oral Squamous Cell Carcinoma · Oropharyngeal Squamous Cell Carcinoma · Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The study is being conducted to evaluate the efficacy and safety of sintilimab in combination with reduction of cycles of chemotherapy (carboplatin and nab-paclitaxel) in patients with oral cavity or oropharyngeal squamous cell carcinoma who are about to undergo surgery. Data obtained in this trial will provide valuable information for planning further prospective clinical trials of anti-PD-1 and other immunotherapies in oral cavity or oropharyngeal squamous cell carcinoma.
This description comes directly from the study's public registry record.
Song Fan, Doctor degrees · 020-81332220 · fansong2@mail.asysu.edu.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-sen Memorial Hospital | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05098119